Martin Clive Hutchings

USPTO Granted Patents = 21 (Patent Applications = 6)

CIPO Patents = 6 (Patent Applications = 3)

EPO Patents = 11 (Patent Applications = 11)

Average Co-Inventor Count = 5.9

ph-index = 9

Forward Citations = 839(Granted Patents)

Location History:

Wokingham, GB (1999 - 2010)
Berkshire, GB (2002 - 2012)
Slough Berkshire, GB (2013)
Slough, GB (2013 - 2024)

Company Filing History:

Celltech Therapeutics Limited

where one patent can have more than one assignee

Years Active: 1999-2024

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11912721 - Fused pentacyclic imidazole derivatives (2024-02-27),

2. 10980814 - Fused pentacyclic imidazole derivatives as modulators of TNF activity (2021-04-20),

3. 10906919 - Fused pentacyclic imidazole derivatives (2021-02-02),

4. 10202405 - Fused pentacyclic imidazole derivatives (2019-02-12),

5. 9873703 - Imidazopyridazine derivatives as modulators of TNF activity (2018-01-23),

6. 9815797 - Fused bicyclic heteroaromatic derivatives as modulators of TNF activity (2017-11-14),

7. 9550737 - TNF -α modulating benzimidazoles (2017-01-24),

8. 9309243 - Imidazopyridine derivatives as modulators of TNF activity (2016-04-12),

9. 8604051 - Thieno-pyridine derivatives as MEK inhibitors (2013-12-10),

10. 8487101 - Thieno-pyridine derivatives as MEK inhibitors (2013-07-16),

11. 8394822 - Thieno-pyridine derivatives as MEK inhibitors (2013-03-12),

12. 8350037 - Thieno-pyridine derivatives as MEK inhibitors (2013-01-08),

13. 8283359 - Thieno-pyridine derivatives as MEK inhibitors (2012-10-09),

14. 7795256 - Thieno-pyridinone derivatives as kinase inhibitors (2010-09-14),

15. 6579983 - 5-cyano-2-aminopyrimidine derivatives (2003-06-17),

Title: Martin Clive Hutchings: Inspiring the Next Generation of Inventors

Introduction:

Martin Clive Hutchings, a prolific inventor based in Slough, GB, is renowned for his dedication to pushing the boundaries of innovation and creativity. With a remarkable portfolio of 21 patents, Hutchings continues to inspire the next generation of inventors with his groundbreaking work.

Latest Patents:

Hutchings' latest patents revolve around fused pentacyclic imidazole derivatives, which serve as potent modulators of human TNFα activity. These compounds show potential in treating a wide range of human ailments, from autoimmune and inflammatory disorders to oncological disorders. Specifically, his inventions focus on 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.

Career Highlights:

Having worked with esteemed companies like UCB Pharma S.A. and Celltech Therapeutics Limited, Hutchings has made significant contributions to the pharmaceutical industry. His dedication to innovation and commitment to developing novel solutions have earned him a stellar reputation in the field.

Collaborations:

Throughout his career, Hutchings has collaborated with talented individuals such as Daniel Christopher Brookings and James Andrew Johnson. These partnerships have led to the creation of groundbreaking inventions that have the potential to revolutionize the way we approach various human ailments.

Conclusion:

Martin Clive Hutchings' passion for innovation and creativity shines through in his impressive body of work. By pushing the boundaries of what is possible in the field of pharmaceuticals, Hutchings continues to inspire and pave the way for the next generation of inventors.

This text is generated by artificial intelligence and may not be accurate.